Matthew R Davis1, Minh-Vu H Nguyen2, Monica A Donnelley1, George R Thompson Iii3,4. 1. Department of Pharmacy, University of California, Davis Health, Stockton Blvd., Sacramento, CA, USA. 2. Department of Internal Medicine, University of California, Davis Health, V St., Sacramento, CA, USA. 3. Department of Medical Microbiology and Immunology, University of California, Med Science Dr., Davis, CA, USA. 4. Department of Internal Medicine, Division of Infectious Diseases, University of California, Davis Health, V Street, Suite G500, Sacramento, CA, USA.
Abstract
BACKGROUND: Fluconazole is a commonly prescribed first-generation triazole antifungal. Although the toxicity profile of fluconazole has been evaluated in clinical trials, there are scant data regarding its tolerability with long-term therapy. Treatment guidelines for coccidioidomycosis recommend fluconazole therapy and severe or disseminated infections can require lifelong treatment. OBJECTIVES: To assess the prevalence of long-term fluconazole adverse effects, their consequences for antifungal therapy, time to adverse effects and the association between dosing regimen or fluconazole serum level and adverse effect status. METHODS: We conducted a single-centre, retrospective study of adult patients (≥18 years) with proven or probable coccidioidomycosis receiving long-term fluconazole therapy for an intended duration of ≥28 days. RESULTS: Out of 124 patients included, 64 (51.6%) experienced adverse effects. The most common adverse effects were xerosis (16.9%), alopecia (16.1%) and fatigue (11.3%). Of the 64 patients experiencing adverse effects, 42 (65.6%) required a therapeutic intervention such as dose reduction, discontinuation or switch to a new antifungal. Patients experiencing adverse effects were prescribed higher total daily fluconazole doses (6.7 versus 5.7 mg/kg; P < 0.01). The median therapeutic drug levels did not differ significantly between patients who experienced adverse effects and those who did not (36.1 versus 28.1 mg/L; P = 0.35). CONCLUSIONS: A significant number of patients receiving long-term fluconazole therapy for coccidioidomycosis experienced adverse effects. Of these, around two-thirds required a therapeutic change. We believe these findings are representative of the adverse effect profile of long-term fluconazole therapy as it is used in clinical practice for coccidioidomycosis as opposed to use in clinical trials.
BACKGROUND:Fluconazole is a commonly prescribed first-generation triazole antifungal. Although the toxicity profile of fluconazole has been evaluated in clinical trials, there are scant data regarding its tolerability with long-term therapy. Treatment guidelines for coccidioidomycosis recommend fluconazole therapy and severe or disseminated infections can require lifelong treatment. OBJECTIVES: To assess the prevalence of long-term fluconazole adverse effects, their consequences for antifungal therapy, time to adverse effects and the association between dosing regimen or fluconazole serum level and adverse effect status. METHODS: We conducted a single-centre, retrospective study of adult patients (≥18 years) with proven or probable coccidioidomycosis receiving long-term fluconazole therapy for an intended duration of ≥28 days. RESULTS: Out of 124 patients included, 64 (51.6%) experienced adverse effects. The most common adverse effects were xerosis (16.9%), alopecia (16.1%) and fatigue (11.3%). Of the 64 patients experiencing adverse effects, 42 (65.6%) required a therapeutic intervention such as dose reduction, discontinuation or switch to a new antifungal. Patients experiencing adverse effects were prescribed higher total daily fluconazole doses (6.7 versus 5.7 mg/kg; P < 0.01). The median therapeutic drug levels did not differ significantly between patients who experienced adverse effects and those who did not (36.1 versus 28.1 mg/L; P = 0.35). CONCLUSIONS: A significant number of patients receiving long-term fluconazole therapy for coccidioidomycosis experienced adverse effects. Of these, around two-thirds required a therapeutic change. We believe these findings are representative of the adverse effect profile of long-term fluconazole therapy as it is used in clinical practice for coccidioidomycosis as opposed to use in clinical trials.
Authors: Vivian Lee; Michael D Gober; Hasan Bashir; Conor O'Day; Ian A Blair; Clementina Mesaros; Liwei Weng; Andrew Huang; Aaron Chen; Rachel Tang; Vince Anagnos; JiLon Li; Sophie Roling; Emilija Sagaityte; Andrew Wang; Chenyan Lin; Christopher Yeh; Cem Atillasoy; Christine Marshall; Tzvete Dentchev; Todd Ridky; John T Seykora Journal: Exp Dermatol Date: 2019-10-29 Impact factor: 3.960
Authors: Supavit Chesdachai; Radha Rajasingham; Melanie R Nicol; David B Meya; Felix Bongomin; Mahsa Abassi; Caleb Skipper; Richard Kwizera; Joshua Rhein; David R Boulware Journal: Open Forum Infect Dis Date: 2019-10-01 Impact factor: 3.835
Authors: Marley C Caballero Van Dyke; George R Thompson; John N Galgiani; Bridget M Barker Journal: Front Immunol Date: 2019-09-11 Impact factor: 7.561
Authors: Safoura Sheikh Rezaei; Hana Šinkovec; Alexander Schöberl; Christoph Rinner; Georg Heinze; Michael Wolzt; Walter Gall Journal: BMC Geriatr Date: 2021-02-10 Impact factor: 3.921
Authors: Julia A Messina; Eileen K Maziarz; John Galgiani; Jonathan T Truong; Aung K Htoo; Arash Heidari; Royce H Johnson; Aneesh T Narang; Fariba M Donovan; Marion Ewell; Antonino Catanzaro; George R Thompson; Neil M Ampel; John R Perfect; Susanna Naggie; Emmanuel B Walter Journal: Contemp Clin Trials Commun Date: 2021-10-14